Radio-immunotherapy
One of AECA's first scientific initiatives supported Eurasian and U.S. collaborative research to develop radiopharmaceuticals for the detection and treatment of cancer.
Through this partnership, Eurasian scientific partnering institutes provided reliable, cost-effective access to high-quality nuclear technology and medical radioisotopes to scientists at Fox Chase Cancer Center and premier, Maryland-based research facilities. Under the auspices of AECA, scientists successfully developed anti-tumor antibody markers for use in imaging technology detection, as well as refined the technique of staging of cancer using unique radionuclides.
The partnership between scientific collaborators has facilitated the development and production of next-generation antibody-based radiotracers, and generated multiple scientific abstract presentations and peer-reviewed journal publications covering the innovative use of radioisotopes in the detection and treatment of ovarian, renal, and breast cancers.